Пожалуйста, помоги со статьёй:
Clinical Dose Preparation of [177Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [177Lu]LuCl3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression
Sreeja Raj Menon et al.
Cancer Biotherapy & Radiopharmaceuticals Vol. 37, No. 5
- DOI:
http://dx.doi.org/https://doi.org/10.1089/cbr.2021.0230
